Search

Descubra cómo MSK utiliza el enfoque de observación y espera para el cáncer de recto, que permite preservar la calidad de vida de los pacientes al tratar con éxito el cáncer de recto sin necesidad de extirpar el recto.

… Friday, February 28, 2025 Existe una alternativa para tratar a algunos pacientes con cáncer de recto que permite evitar la extirpación quirúrgica del recto y los efectos secundarios relacionados, que pueden incluir cambios en la función sexual y la fertilidad y la posibilidad de tener que usar una bolsa

Learn about a clinical trial that used immunotherapy alone to treat people with several different types of cancer, meaning they did not need to undergo surgery, radiation, or chemotherapy.

… Sunday, April 27, 2025 An approach pioneered at Memorial Sloan Kettering Cancer Center (MSK) that caused rectal cancer tumors with a specific genetic mutation to disappear in 100% of clinical trial participants has been expanded to treat other types of cancer, including stomach (gastric) , colon , esophageal

Obtenga información sobre un ensayo clínico en el que se utilizó únicamente inmunoterapia para tratar a personas con varios tipos diferentes de cáncer, lo que significa que no tuvieron que someterse a cirugía, radioterapia ni quimioterapia.

… Sunday, April 27, 2025 Un enfoque en el que Memorial Sloan Kettering Cancer Center (MSK) fue pionero y que hizo que los tumores de cáncer de recto con una mutación genética específica desaparecieran en el 100 % de los participantes en el ensayo clínico se ha ampliado para tratar otros tipos de cáncer

Using genetic engineering, Memorial Sloan Kettering Cancer Center (MSK) physician-scientist Christopher Klebanoff, MD, has led a team of researchers to create a “cloak” that protects cancer-fighting T white blood cells, such as chimeric antigen receptor T cells, from self-destructing. During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness. The use of “genetic cloaking” prevents immune cell apoptosis, enhancing the effectiveness of cellular immunotherapies for liquid and solid cancers in mouse models. This new technique is also effective in protecting human cancer-fighting immune cells. These findings lay the groundwork for a potentially universal gene-engineering strategy to safely increase the potency of cellular immunotherapies for a broad range of cancers.

… Tuesday, January 29, 2019 Bottom Line: Using genetic engineering, Memorial Sloan Kettering Cancer Center (MSK) physician-scientist Christopher Klebanoff, MD , has led a team of researchers to create a “cloak” that protects cancer-fighting T white blood cells, such as chimeric antigen receptor T cells

The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.

… Sunday, September 20, 2020 Summary In a study of people with lung cancer whose tumors contained the mutation targeted by sotorasib, 52 of 59 patients experienced disease control, which means that their tumors stopped growing. Update: On January 30, 2021, Memorial Sloan Kettering lung cancer expert Bob

A new tool developed by MSK scientists allows users to map metabolic data from kidney cancer tumors.

… Friday, February 5, 2016 Summary Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may

Awarded annually since 1955, the Sloan Research Fellowships honor exceptional U.S. and Canadian researchers whose creativity, leadership, innovation, and research accomplishments make them stand out as the next generation of leaders.

… Thursday, February 22, 2024 Memorial Sloan Kettering Cancer Center (MSK)  is proud to announce that  Yael David, PhD , chemical biologist leading The Yael David Lab and Associate Member of the Chemical Biology Program , has been selected as a 2024 Alfred P. Sloan Research Fellow in Chemistry. Dr. David

Learn what Zepbound, Wegovy, Ozempic and other weight loss drugs mean for cancer risk and treatment, from an expert at MSK.

… Tuesday, March 10, 2026 Ozempic, Zepbound, Wegovy, and related weight loss drugs have become some of the world’s most talked about medications in a remarkably short time. A growing body of research suggests these drugs may also be an important tool in reducing cancer related to obesity and higher levels

Discover how microbiome research is revealing the role that bacteria play in cancer treatment.

… Thursday, August 11, 2016 Summary Studies that analyze the microbiome — the community of organisms that live in the body — in cancer patients are revealing new findings about the connection between bacteria and health in cancer patients. Highlights One study has shown how microbes may trigger colitis

For men with inherited mutations in BRCA1 and BRCA2, a new program at MSK provides a “one-stop shop” for highly personalized cancer screening and surveillance.

… Thursday, June 16, 2022 Perhaps the best known of all the cancer predisposition genes are inherited mutations in the genes BRCA1 and BRCA2 . They were originally associated with an increased risk of breast and ovarian cancers . Later studies revealed they also raised the risk of prostate and pancreatic